Ledipasvir
- Generic Name
- Ledipasvir
- Brand Names
- Harvoni
- Drug Type
- Small Molecule
- Chemical Formula
- C49H54F2N8O6
- CAS Number
- 1256388-51-8
- Unique Ingredient Identifier
- 013TE6E4WV
- Background
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting ...
- Indication
When used in combination with the antiviral medication sofosbuvir, ledipasvir is indicated for the treatment of treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with the following conditions:
Its use has also proven successful in the treatment of HCV in patients co-infected with HIV .
- Associated Conditions
- Chronic Hepatitis C Genotype 1, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-13
- Target Recruit Count
- 150
- Registration Number
- NCT02771405
- Locations
- 🇪🇬
Amr Maged, Cairo, Egypt
Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Instituto de Investigación Marqués de Valdecilla
- Target Recruit Count
- 64
- Registration Number
- NCT02768961
- Locations
- 🇪🇸
Penitentiary "El Dueso". Cantabria. Spain, Santoña, Cantabria, Spain
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT02705534
- Locations
- 🇮🇷
Shariati Hospital, Tehran, Iran, Islamic Republic of
Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
- Conditions
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 120
- Registration Number
- NCT02405013
- Locations
- 🇨🇮
CHU de Youpougon - Service de Gastro-entéro-hépatologie, Abidjan, Côte D'Ivoire
🇨🇲Clinique de la Cathédrale, Yaoundé, Cameroon
🇸🇳CHU Fann, Service des Maladies Infectieuses, Dakar, Senegal
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Valme University Hospital
- Target Recruit Count
- 1128
- Registration Number
- NCT02333292
- Locations
- 🇪🇸
Valme University Hospital, Seville, Andalusia, Spain
Combination Therapy for Chronic Hepatitis C Infection
- Conditions
- Interventions
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2017-06-08
- Target Recruit Count
- 229
- Registration Number
- NCT01805882
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸Family Medical and Conseling Services, Washington, D.C., District of Columbia, United States
🇺🇸Unity Health Care, Inc./DC General, Washington, D.C., District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.